Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2004 1
2010 1
2011 1
2012 2
2013 1
2014 1
2015 1
2016 1
2018 1
2019 1
2020 2
2021 2
2022 4
2023 3
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Paz-Ares L, et al. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4. Lancet. 2019. PMID: 31590988 Clinical Trial.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Goldman JW, et al. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. Lancet Oncol. 2021. PMID: 33285097 Clinical Trial.
Genome-wide tandem repeat expansions contribute to schizophrenia risk.
Mojarad BA, Engchuan W, Trost B, Backstrom I, Yin Y, Thiruvahindrapuram B, Pallotto L, Mitina A, Khan M, Pellecchia G, Haque B, Guo K, Heung T, Costain G, Scherer SW, Marshall CR, Pearson CE, Bassett AS, Yuen RKC. Mojarad BA, et al. Among authors: haque b. Mol Psychiatry. 2022 Sep;27(9):3692-3698. doi: 10.1038/s41380-022-01575-x. Epub 2022 May 12. Mol Psychiatry. 2022. PMID: 35546631 Free PMC article.
The Consortium on Vulnerability to Externalizing Disorders and Addictions (c-VEDA): an accelerated longitudinal cohort of children and adolescents in India.
Zhang Y, Vaidya N, Iyengar U, Sharma E, Holla B, Ahuja CK, Barker GJ, Basu D, Bharath RD, Chakrabarti A, Desrivieres S, Elliott P, Fernandes G, Gourisankar A, Heron J, Hickman M, Jacob P, Jain S, Jayarajan D, Kalyanram K, Kartik K, Krishna M, Krishnaveni G, Kumar K, Kumaran K, Kuriyan R, Murthy P, Orfanos DP, Purushottam M, Rangaswamy M, Kupard SS, Singh L, Singh R, Subodh BN, Thennarasu K, Toledano M, Varghese M, Benegal V, Schumann G; c-VEDA consortium. Zhang Y, et al. Mol Psychiatry. 2020 Aug;25(8):1618-1630. doi: 10.1038/s41380-020-0656-1. Epub 2020 Mar 12. Mol Psychiatry. 2020. PMID: 32203154 Review.
Stroke in Bangladeshi patients and risk factor.
Mohammad QD, Habib M, Mondal BA, Chowdhury RN, Hasan MH, Hoque MA, Rahman KM, Khan SU, Chowdhury AH, Haque B. Mohammad QD, et al. Among authors: haque b. Mymensingh Med J. 2014 Jul;23(3):520-9. Mymensingh Med J. 2014. PMID: 25178605
23 results